CFS Clinical (CFS), a provider focused on the business and financial management activities for clinical trials, announced the launch of its upgraded technology platform and new tax consulting services.
The InSite™ technology platform offers transparency for clinical trial operations, with reporting capabilities offering further visibility into investigator grant payments and study startup – including grant spend forecasting and modeling, Sunshine & global transparency compliance, enterprise site profiling, and more.
“CFS Clinical is the leader in our space and has always been a pioneer in clinical business operations. By adapting our solutions to the changing needs of sponsors, CROs, and sites, CFS continues to lead the way in transforming the business of clinical trials,” says Kevin Williams MBA/MS, Vice President of Corporate Development and Marketing for CFS Clinical.
In addition to the expanded business intelligence capabilities, CFS Clinical officially launched its Tax Consulting Service in January to help clients sort out the vast complexities of paying investigators globally.
“VAT rates range from 10-29%, and those rates are applied to millions of dollars of global grant payments.” states April Mulroney CPA, CA, Vice President of Global Tax, Treasury and Client Services based in CFS’s UK office. “CFS experts formalized this unique service to help our clients minimize financial risk and manage tax exposure on the largest line item in their clinical trial budget – the grant payments.”
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.
New FDA Initiative Reveals Common Reasons for Drug Application Rejection
July 11th 2025By publishing more than 200 complete response letters, the FDA is offering new visibility into the issues that most often delay drug approvals, including safety concerns, trial design flaws, and manufacturing gaps.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.